Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake

Journal of Immunology

Volumn 163, Issue 3, 1999, Pages 1398-1408

  Todryk, Stephen ^a   Melcher, Alan A ^a,b   Hardwick, Nicola ^a   Linardakis, Emmanouela ^a   Bateman, Andrew ^a,b   Colombo, Mario P ^c   Stoppacciaro, Antonella ^a,d   Vile, Richard G ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b MAYO CLINIC   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYTOKINE; GAMMA INTERFERON; GANCICLOVIR; HEAT SHOCK PROTEIN 70; INTERLEUKIN 12; THYMIDINE KINASE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL INFILTRATION; CELL SPECIFICITY; CYTOKINE PRODUCTION; DENDRITIC CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; STEM CELL; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY;

ANIMALS; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL MOVEMENT; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HSP70 HEAT-SHOCK PROTEINS; IMMUNOPHENOTYPING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; TH1 CELLS; TUMOR ESCAPE;

EID: 0033179274     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Colombo, M. P., A. Modesti, O. Parmiani, and G. Forni. 1992. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 52:4853.
2. Melcher, A. A., S. Todryk, N. Hardwick, M. Ford, M. Jacobson, and R. G. Vile. 1998. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 4:581.
3. Vile, R. G., and H. Chong. 1996. Immunotherapy: combinatorial molecular immunotherapy: a synthesis and suggestions. Cancer Metastasis Rev. 15:351.
4. Pardoll, D. M. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:399.
5. Hellstrom, K. E., I. Hellstrom, and L. Chen. 1995. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev. 145:123.
6. Nabel, G. J., A. Chang, E. G. Nabel, G. Plautz, B. A. Fox, L. Huang, and S. Shu. 1992. Clinical protocol: immunotherapy of malignancy by in vivo gene transfer into tumors. Hum. Gene Ther. 3:399.
7. Hock, H., M. Dorsch, U. Kunzendorf, K. Uberla, Z. Qin, T. Diamanstein, and T. Blankenstein. 1993. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res. 53:714.
8. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
9. Maass, G., W. Schmidt, M. Berger, F. Schilcher, F. Koszik, A. Schneeberger, G. Stingl, M. Birnstiel, and T. Schweighoffer. 1995. Priming of tumor specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA 92:5540.
10. Cayeux, S., G. Richter, G. Noffz, B. Dorken, and T. Biankenstein. 1997. Influence of gene-modified (IL-7, IL-4 and B7) tumor cell vaccines on tumor antigen presentation. J. Immunol. 158:2834.
11. Huang, A. Y. C., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961.
12. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete marine granulocyte macrophage colony stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
13. Levitsky, H. I., A. Lazenby, R. J. Hayashi, and D. Pardoll. 1994. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med. 179:1215.
14. Shen, Z., G. Reznikoff, G. Dranoff, and K. L. Rock. 1997. Cloned dendritic cells can present exogenous antigens on both class I and class II molecules. J. Immunol. 158:2723.
15. Houghton, A. N. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1.
16. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
17. Fuchs, E. J., and P. Matzinger. 1996. Is cancer dangerous to the immune system? Semin. Immunol. 8:271.
18. Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86.
19. Srivastava, P. K., A. Menoret, S. Basu, R. J. Binder, and K. L. McQuade. 1998. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8:657.
20. Vile, R. G., J. A. Nelson, S. Castleden, H. Chong, and I. R. Hart. 1994. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component Cancer Res. 54:6228.
21. Castleden, S. A., H. Chong, I. Garcia-Ribas, A. A. Melcher, G. Hutchinson, B. Roberts, I. R. Hart, and R. G. Vile. 1997. A family of bicistronic vectors to enhance both local and systemic anti tumor effects of HSVtk or cytokine expression in a murine melanoma model. Hum. Gene Ther. 8:2087.
22. Freeman, S. M., R. Ramesh, and A. J. Marrogi. 1997. Immune system in suicide gene therapy. Lancet 349:2.
23. Barba, D., J. Hardin, M. Sadelain, and F. H. Gage. 1994. Development of anti tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91:4348.
24. Caruso, M., Y. Panis, S. Gagandeep, D. Houssin, J. L. Salzmann, and D. Klatzmann. 1993. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA 90:7024.
25. Consalvo, M., C. A. Mullen, A. Modesti, P. Musiani, A. Allione, F. Cavallo, M. Giovarelli, and G. Forni. 1995. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J. Immunol. 154:5302.
26. Mullen, C. A., M. M. Coale, R. Lowe, and R. M. Blaese. 1994. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 54: 1503.
27. Vile, R. G., S. C. Castleden, J. Marshall, R. Camplejohn, C. Upton, and H. Chong. 1997. Generation of an anti-tumor immune response in a non-immunogenic tumor: HSVtk-killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoral cytokine expression. Int. J. Cancer 71:267.
28. Matzinger, P. 1994. Tolerance, danger and the extended family. Annu. Rev. Immunol. 12:991.
29. Finkelman, F. D., A. Lees, R. Birnbaum, W. Gause, and S. C. Morris. 1996. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J. Immunol. 157:1406.
30. Srivastava, P. K., and H. Udono. 1994. Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 6:728.
31. Tamura, Y., P. Peng, K. Liu, M. Daou, and P. K. Srivastava. 1997. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117.
32. Suto, R., and P. K. Srivastava. 1995. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269:1585.
33. Srivastava, P., H. Udono, N. E. Blachere, and Z. Li. 1994. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39:93.
34. Arnold, D., S. Faath, H.-G. Rammensee, and H. Schild. 1995. Cross priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 182:885.
35. Suzue, K., X. Zhou, H. N. Eisen, and R. A. Young. 1997. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc. Natl. Acad. Sci. USA 94:13146.
36. Li, Z. 1997. Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines. Semin. Immunol. 9:315.
37. Wei, Y.-q., X. Zhao, Y. Kariya, H. Fukata, K. Teshigawara, and A. Uchida. 1996. Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of yd T cells and heat shock protein 70. Cancer Res. 56:1104.
38. Rajasekar, R., G. K. Sim, and A. Augustin. 1990. Self heat shock and γδ T-cell reactivity. Proc. Natl. Acad. Sci. USA 87:1767.
39. Lukacs, K. V., D. B. Lowrie, R. W. Stokes, and M. J. Colston. 1993. Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors. J. Exp. Med. 178:343.
40. Lukacs, K. V., A. Nakakes, C. J. Atkins, D. B. Lowrie, and M. J. Colston. 1997. In vivo gene therapy of malignant tumors with heat shock protein-65 gene. Gene Ther. 4:346.
41. Vile, R. G., and I. R. Hart, 1993. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53:962.
42. Franks, L., and V. Hemmings. 1978. A cell line from an induced carcinoma of a mouse rectum. J. Pathol. 124:35.
43. Inaba, K., M. Inaba, M. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte macrophage colony stimulating factor. J. Exp. Med. 176:1693.
44. Altman, D. G. 1991. Analysis of survival times. In Practical Statistics for Medical Research. D. G. Altman, ed. Chapman and Hall, London, p. 365.
45. Abdel-Wahab, Z., M. Dar, S. Osanto, T. Fong, C. E. Vervaert, D. Hester, D. Jolly, and H. F. Seigler. 1997. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or γ interferon. Cancer Gene Ther. 4:33.
46. Rodolfo, M., C. Zilocchi, C. Melani, B. Cappetti, I. Arioli, G. Parmiani, and M. P. Colombo. 1996. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens: comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J. Immunol. 157:5536.
47. Multhoff, G., C. Botzler, L. Jennen, J. Schmidt, J. Ellwart, and R. Issels. 1997. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J. Immunol. 158:4341.
48. Wells, A. D., S. K. Rai, M. S. Salvato, H. Band, and M. Malkovsky. 1997. Hsp-72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int. Immunol. 10:609.
49. Fakhrai, H., D. L. Shawler, R. Gjerset, R. K. Naviaux, J. Koziol, I. Royston, and R. E. Sobol. 1995. Cytokine gene therapy with interleukin-2 transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther. 6:591.
50. Golumbek, P. T., R. Azhai, E. M. Jaffee, H. I. Levitsky, A. Lazenby, K. Leong, and D. M. Pardoll. 1993. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. 53:5841.
51. Kim, T. S., and E. P. Cohen. 1994. lnterleukin-2 secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res. 54:2531.
52. + T cells in vivo. Proc. Natl. Acad. Sci. USA 91:3077.
53. Matzinger, P. 1998. An innate sense of danger. Semin. Immunol. 10:399.
54. Mitchell, D. A., S. K. Nair, and E. Gilboa. 1998. Dendritic cell/macrophage precursors capture exogenous antigen for MHC class 1 presentation by dendritic cells. Eur. J. Immunol. 28:1923.